DE2511576C2 - Metformin-clofibrat, Verfahren zu seiner Herstellung und dieses enthaltendes Arzneimittel - Google Patents
Metformin-clofibrat, Verfahren zu seiner Herstellung und dieses enthaltendes ArzneimittelInfo
- Publication number
- DE2511576C2 DE2511576C2 DE2511576A DE2511576A DE2511576C2 DE 2511576 C2 DE2511576 C2 DE 2511576C2 DE 2511576 A DE2511576 A DE 2511576A DE 2511576 A DE2511576 A DE 2511576A DE 2511576 C2 DE2511576 C2 DE 2511576C2
- Authority
- DE
- Germany
- Prior art keywords
- metformin
- clofibrate
- salt
- preparation
- product containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims description 29
- 229960003105 metformin Drugs 0.000 title claims description 24
- 229960001214 clofibrate Drugs 0.000 title claims description 8
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 4
- 229940126601 medicinal product Drugs 0.000 title 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 claims description 12
- 239000003315 2-(4-chlorophenoxy)-2-methylpropanoic acid Substances 0.000 claims description 10
- 229950008441 clofibric acid Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960004329 metformin hydrochloride Drugs 0.000 description 5
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YMCZETULMSWVBI-UHFFFAOYSA-N 2-(4-chlorophenoxy)acetic acid;3-(diaminomethylidene)-1,1-dimethylguanidine Chemical compound CN(C)C(=N)N=C(N)N.OC(=O)COC1=CC=C(Cl)C=C1 YMCZETULMSWVBI-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- -1 p-chlorophenoxy Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7409963A FR2264525B1 (cs) | 1974-03-22 | 1974-03-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2511576A1 DE2511576A1 (de) | 1975-09-25 |
| DE2511576C2 true DE2511576C2 (de) | 1983-07-07 |
Family
ID=9136732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2511576A Expired DE2511576C2 (de) | 1974-03-22 | 1975-03-17 | Metformin-clofibrat, Verfahren zu seiner Herstellung und dieses enthaltendes Arzneimittel |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JPS5526134B2 (cs) |
| AT (1) | AT346856B (cs) |
| BE (1) | BE826999A (cs) |
| CA (1) | CA1062280A (cs) |
| CH (1) | CH609669A5 (cs) |
| DE (1) | DE2511576C2 (cs) |
| ES (1) | ES435898A1 (cs) |
| FR (1) | FR2264525B1 (cs) |
| GB (1) | GB1462316A (cs) |
| LU (1) | LU72102A1 (cs) |
| NL (1) | NL169461C (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
| FR2796551B1 (fr) * | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
| FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR7116M (cs) * | 1968-01-08 | 1969-07-15 | ||
| AT317235B (de) * | 1972-08-22 | 1974-08-26 | Hurka Wilhelm | Verfahren zur Herstellung des neuen 2-(p-Chlorphenoxy)-2-methylpropionsäuresalzes des 1-Phenäthylbiguanids |
-
1974
- 1974-03-22 FR FR7409963A patent/FR2264525B1/fr not_active Expired
-
1975
- 1975-03-17 DE DE2511576A patent/DE2511576C2/de not_active Expired
- 1975-03-20 LU LU72102A patent/LU72102A1/xx unknown
- 1975-03-21 ES ES435898A patent/ES435898A1/es not_active Expired
- 1975-03-21 AT AT217875A patent/AT346856B/de not_active IP Right Cessation
- 1975-03-21 BE BE154602A patent/BE826999A/xx unknown
- 1975-03-21 CA CA222,798A patent/CA1062280A/fr not_active Expired
- 1975-03-21 GB GB1199975A patent/GB1462316A/en not_active Expired
- 1975-03-21 CH CH362775A patent/CH609669A5/xx not_active IP Right Cessation
- 1975-03-22 JP JP3484475A patent/JPS5526134B2/ja not_active Expired
- 1975-03-24 NL NLAANVRAGE7503515,A patent/NL169461C/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES435898A1 (es) | 1976-12-16 |
| AT346856B (de) | 1978-11-27 |
| FR2264525A1 (cs) | 1975-10-17 |
| NL169461B (nl) | 1982-02-16 |
| BE826999A (fr) | 1975-07-16 |
| CA1062280A (fr) | 1979-09-11 |
| LU72102A1 (cs) | 1975-08-20 |
| ATA217875A (de) | 1978-04-15 |
| JPS5526134B2 (cs) | 1980-07-11 |
| NL169461C (nl) | 1982-07-16 |
| CH609669A5 (en) | 1979-03-15 |
| JPS50135043A (cs) | 1975-10-25 |
| FR2264525B1 (cs) | 1977-11-04 |
| DE2511576A1 (de) | 1975-09-25 |
| GB1462316A (en) | 1977-01-26 |
| NL7503515A (nl) | 1975-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2528360A1 (de) | Neue pyrimidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen | |
| CH640249A5 (de) | Germaniumhaltiges organisches polymer und verfahren zu seiner herstellung. | |
| DE2721171A1 (de) | Neues vincaminsalz, seine herstellung und es enthaltende pharmazeutische zubereitungen | |
| DE2433407A1 (de) | Sulfate von hydroxyaethylstaerke | |
| DE2253750C3 (de) | Apovincaminsaure-alkylester, Verfahren zu ihrer Herstellung und pharmazeutische | |
| DE2947624A1 (de) | Beta, gamma -dihydropolyprenylalkohol und diesen enthaltendes blutdrucksenkendes arzneimittel | |
| DE2403122C2 (cs) | ||
| DE2511576C2 (de) | Metformin-clofibrat, Verfahren zu seiner Herstellung und dieses enthaltendes Arzneimittel | |
| DE2725246C2 (cs) | ||
| EP0043548B1 (de) | Salz aus Furosemid oder Piretanid als Säurekomponente und Penbutolol als Basenkomponente sowie Arzneimittel, das beide Komponenten enthält | |
| DE1545772B1 (de) | 7-(3'-Picolylamino-alkyl)-theophylline und deren nikotinsaure Salze | |
| DE1936723C2 (de) | Salze von Chinarindenalkoloiden und Verfahren zu ihrer Herstellung | |
| DE2446640A1 (de) | Neue gentamicinderivate, verfahren zur herstellung derselben und diese enthaltende antibiotisch wirksame zusammensetzungen | |
| DE3310584C2 (cs) | ||
| DE1493618A1 (de) | Cumarinderivate und ein Verfahren zu ihrer Herstellung | |
| DE1695832C3 (de) | B1,3-biphenylpyrazolin-Derivate und Verfahren zu ihrer Herstellung | |
| DE69328357T2 (de) | Komplex von 2-aminoäthansulfonsäure und zink | |
| DE2244737B2 (de) | H-o-ChlorphenyD-2-tert-butylaminoäthanol, Verfahren zu dessen Herstellung und Arzneimittel auf dessen Basis | |
| DE1618630C (de) | Salze der alpha-(l-Hydroxy-cycloheexyl)buttersäure mit Betain bzw. Cholin und Verfahren zu ihrer Herstellung | |
| AT213395B (de) | Verfahren zur Herstellung des neuen β-Hydroxybuttersäure-cyclohexylamids | |
| DE2145686C3 (de) | 2-Chlor-S-sulfamylbenzoesäurederivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten | |
| AT288413B (de) | Verfahren zur Herstellung neuer basischer Xanthonderivate und ihrer Salze | |
| DE2932802A1 (de) | Salze von 2,3-dichlor-4-(4-hydroxybenzoyl)-phenoxyessigsaeure | |
| DE3443858A1 (de) | Pharmazeutische zusammensetzungen | |
| DE1670635A1 (de) | o-(ss-Morpholinoaethoxy) diphenylaether |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OB | Request for examination as to novelty | ||
| OC | Search report available | ||
| OD | Request for examination | ||
| 8126 | Change of the secondary classification |
Free format text: C07C 59/68 A61K 31/205 A61K 31/155 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: LABORATOIRES MERCK CLEVENOT S.A., NOGENT-SUR-MARNE |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: GRUENECKER, A., DIPL.-ING. KINKELDEY, H., DIPL.-ING. DR.-ING. STOCKMAIR, W., DIPL.-ING. DR.-ING. AE.E. CAL TECH SCHUMANN, K., DIPL.-PHYS. DR.RER.NAT. JAKOB, P., DIPL.-ING. BEZOLD, G., DIPL.-CHEM. DR.RER.NAT. MEISTER, W., DIPL.-ING. HILGERS, H., DIPL.-ING. MEYER-PLATH, H., DIPL.-ING. DR.-ING. KINKELDEY, U., DIPL.-BIOL. DR.RER.NAT. BOTT-BODENHAUSEN, M., DIPL.-PHYS. DR.RER.NAT., PAT.-ANW., 8000 MUENCHEN |